Who makes Rifaximin 550 milligram Oral Tablet [XIFAXAN]?

Rifaximin 550 milligram Oral Tablet [XIFAXAN] is developed by Samar Atef Sebaweh Mohammed.

What development phase is Rifaximin 550 milligram Oral Tablet [XIFAXAN] in?

Rifaximin 550 milligram Oral Tablet [XIFAXAN] is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Rifaximin 550 milligram Oral Tablet [XIFAXAN]

Samar Atef Sebaweh Mohammed · FDA-approved active Small molecule Quality 0/100

Rifaximin 550 milligram Oral Tablet [XIFAXAN] is a marketed drug owned by Samar Atef Sebaweh Mohammed, with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, supported by a strong patent protection until 2028. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic name	Rifaximin 550 milligram Oral Tablet [XIFAXAN]
Also known as	xifaxan, TARGAXAN
Sponsor	Samar Atef Sebaweh Mohammed
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rifaximin 550 milligram Oral Tablet [XIFAXAN] CI brief — competitive landscape report
Rifaximin 550 milligram Oral Tablet [XIFAXAN] updates RSS · CI watch RSS
Samar Atef Sebaweh Mohammed portfolio CI